BR112021003023A2 - anticorpos anti-fc epsilon-r1 alfa (fcer1a), moléculas biespecíficas de ligação ao antígeno que ligam fcer1a e cd3, e usos dos mesmos - Google Patents
anticorpos anti-fc epsilon-r1 alfa (fcer1a), moléculas biespecíficas de ligação ao antígeno que ligam fcer1a e cd3, e usos dos mesmos Download PDFInfo
- Publication number
- BR112021003023A2 BR112021003023A2 BR112021003023-9A BR112021003023A BR112021003023A2 BR 112021003023 A2 BR112021003023 A2 BR 112021003023A2 BR 112021003023 A BR112021003023 A BR 112021003023A BR 112021003023 A2 BR112021003023 A2 BR 112021003023A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- binding
- amino acid
- fcεr1α
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721921P | 2018-08-23 | 2018-08-23 | |
| US62/721,921 | 2018-08-23 | ||
| PCT/US2019/047601 WO2020041537A1 (en) | 2018-08-23 | 2019-08-22 | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021003023A2 true BR112021003023A2 (pt) | 2021-05-11 |
Family
ID=67876086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021003023-9A BR112021003023A2 (pt) | 2018-08-23 | 2019-08-22 | anticorpos anti-fc epsilon-r1 alfa (fcer1a), moléculas biespecíficas de ligação ao antígeno que ligam fcer1a e cd3, e usos dos mesmos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11578127B2 (https=) |
| EP (1) | EP3840841A1 (https=) |
| JP (2) | JP7402223B2 (https=) |
| KR (1) | KR20210049863A (https=) |
| CN (1) | CN112888482B (https=) |
| AU (1) | AU2019325565B2 (https=) |
| BR (1) | BR112021003023A2 (https=) |
| CA (1) | CA3109513A1 (https=) |
| CL (2) | CL2021000437A1 (https=) |
| CO (1) | CO2021003608A2 (https=) |
| EA (1) | EA202190601A1 (https=) |
| IL (1) | IL280745B1 (https=) |
| MX (1) | MX2021002165A (https=) |
| MY (1) | MY204368A (https=) |
| PH (1) | PH12021550322A1 (https=) |
| SG (1) | SG11202101608XA (https=) |
| WO (1) | WO2020041537A1 (https=) |
| ZA (1) | ZA202100919B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3109513A1 (en) | 2018-08-23 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| US20230056380A1 (en) * | 2020-01-31 | 2023-02-23 | Randy Leiman Allen | Methods and kit for detection of analytes |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU2005282720B2 (en) | 2004-09-02 | 2011-08-04 | Genentech, Inc. | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| WO2012142286A1 (en) * | 2011-04-12 | 2012-10-18 | University Of Cincinnati | Methods for suppressing allergic reactions |
| WO2012169741A2 (ko) | 2011-06-07 | 2012-12-13 | (주)네오팜 | ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| CN104293738A (zh) | 2013-09-11 | 2015-01-21 | 李莉 | 一种抗人FcεRⅠα亚基单克隆抗体及其应用 |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| SG11201701028SA (en) | 2014-08-13 | 2017-03-30 | Suppremol Gmbh | Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor |
| CN104800164B (zh) | 2015-04-13 | 2017-11-07 | 上海市第一人民医院 | 一种雷公藤免疫纳米粒及用途 |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| CA3020633A1 (en) | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| CA3109513A1 (en) | 2018-08-23 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
-
2019
- 2019-08-22 CA CA3109513A patent/CA3109513A1/en active Pending
- 2019-08-22 BR BR112021003023-9A patent/BR112021003023A2/pt unknown
- 2019-08-22 KR KR1020217008580A patent/KR20210049863A/ko active Pending
- 2019-08-22 EP EP19765582.2A patent/EP3840841A1/en active Pending
- 2019-08-22 WO PCT/US2019/047601 patent/WO2020041537A1/en not_active Ceased
- 2019-08-22 MY MYPI2021000853A patent/MY204368A/en unknown
- 2019-08-22 JP JP2021510030A patent/JP7402223B2/ja active Active
- 2019-08-22 SG SG11202101608XA patent/SG11202101608XA/en unknown
- 2019-08-22 CN CN201980069380.5A patent/CN112888482B/zh active Active
- 2019-08-22 IL IL280745A patent/IL280745B1/en unknown
- 2019-08-22 EA EA202190601A patent/EA202190601A1/ru unknown
- 2019-08-22 US US16/547,910 patent/US11578127B2/en active Active
- 2019-08-22 AU AU2019325565A patent/AU2019325565B2/en active Active
- 2019-08-22 MX MX2021002165A patent/MX2021002165A/es unknown
-
2021
- 2021-02-10 ZA ZA2021/00919A patent/ZA202100919B/en unknown
- 2021-02-15 PH PH12021550322A patent/PH12021550322A1/en unknown
- 2021-02-19 CL CL2021000437A patent/CL2021000437A1/es unknown
- 2021-03-19 CO CONC2021/0003608A patent/CO2021003608A2/es unknown
-
2023
- 2023-01-12 US US18/153,522 patent/US12441797B2/en active Active
- 2023-02-13 CL CL2023000442A patent/CL2023000442A1/es unknown
- 2023-10-03 JP JP2023172194A patent/JP7541167B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7402223B2 (ja) | 2023-12-20 |
| AU2019325565A1 (en) | 2021-03-11 |
| CN112888482B (zh) | 2024-06-25 |
| WO2020041537A1 (en) | 2020-02-27 |
| SG11202101608XA (en) | 2021-03-30 |
| US12441797B2 (en) | 2025-10-14 |
| US20230331845A1 (en) | 2023-10-19 |
| US11578127B2 (en) | 2023-02-14 |
| EP3840841A1 (en) | 2021-06-30 |
| KR20210049863A (ko) | 2021-05-06 |
| CL2023000442A1 (es) | 2023-11-24 |
| JP2021533806A (ja) | 2021-12-09 |
| WO2020041537A8 (en) | 2020-09-10 |
| JP7541167B2 (ja) | 2024-08-27 |
| CL2021000437A1 (es) | 2021-09-03 |
| CA3109513A1 (en) | 2020-02-27 |
| US20200062844A1 (en) | 2020-02-27 |
| MY204368A (en) | 2024-08-26 |
| CN112888482A (zh) | 2021-06-01 |
| JP2023171909A (ja) | 2023-12-05 |
| AU2019325565B2 (en) | 2025-09-04 |
| IL280745B1 (en) | 2026-02-01 |
| IL280745A (en) | 2021-04-29 |
| EA202190601A1 (ru) | 2021-07-14 |
| ZA202100919B (en) | 2025-10-29 |
| CO2021003608A2 (es) | 2021-04-30 |
| PH12021550322A1 (en) | 2021-10-04 |
| MX2021002165A (es) | 2021-07-16 |
| NZ772900A (en) | 2025-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI838389B (zh) | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 | |
| TWI728990B (zh) | 抗ｐｓｍａ抗體，結合ｐｓｍａ與ｃｄ３之雙特異性抗原結合分子，及其用途 | |
| TWI688573B (zh) | 抗ｃｄ-３抗體，結合至ｃｄ３及ｃｄ２０的雙專一性抗原結合分子，及其用途 | |
| CN114929343B (zh) | 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法 | |
| JP2021090461A (ja) | レプチン受容体を活性化させる抗原結合タンパク質 | |
| BR112020012011A2 (pt) | moléculas de ligação a antígeno biespecífica isolada e de ligação a antígeno biespecífica ou cadeia de imunoglobulina, composição farmacêutica, recipiente ou dispositivo de injeção, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, métodos para tratar uma doença ou condição, para tratar uma condição de lipodistrofia em um sujeito, para produzir uma molécula de ligação a antígeno biespecífica, e, para administrar uma molécula de ligação a antígeno biespecífica isolada ou composição farmacêutica. | |
| JP2019532056A (ja) | 抗ｓｔｅａｐ２抗体、抗体−薬物複合体、およびｓｔｅａｐ２とｃｄ３を結合する二重特異性抗原結合分子、ならびにそれらの使用 | |
| AU2014240392A1 (en) | Human antibodies to Nav1.7 | |
| RS67417B1 (sr) | Humana antitela na fel d1 i postupci njihove upotrebe | |
| US12441797B2 (en) | Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bind FCϵR1α and CD3, and uses thereof | |
| EA048275B1 (ru) | АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FcER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FcER1A И CD3, И ИХ ПРИМЕНЕНИЕ | |
| BR112015020470B1 (pt) | Anticorpo monoclonal humano isolado anti-il-33 ou fragmento de ligação ao antígeno do mesmo, seus usos, molécula de ácido nucleico isolada, vetor de expressão, e composição farmacêutica | |
| BR112017005692B1 (pt) | Anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |